Mild to Moderate Psoriasis
Conditions
Interventions
Sponsors
Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venerology, Shandong First Medical University & Shandong Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years old; 2.During screening, the clinical diagnosis is mild or moderate psoriasis; including but not limited to guttate psoriasis and plaque psoriasis. Note: For the diagnosis of mild to moderate psoriasis, it is recommended to meet the following conditions simultaneously: at baseline, mild: BSA < 3%, PASI < 3, DLQI < 6; moderate: BSA 3% to <10%, PASI 3 to <10, DLQI 6 to <10. 3.Patients who are assessed by a clinician to be suitable for treatment with Xeligekimab Injection and are planning to receive Xeligekimab Injection treatment for the first time; 4.Those who voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Drug-induced psoriasis (such as new-onset psoriasis or worsening of psoriasis caused by ß-blockers, calcium channel blockers, or lithium); 2.Allergic to the active ingredient of XeligekimabInjection or any excipients; 3.Patients with other contraindications listed in the package insert; 4.Patients who are currently participating in other clinical studies; 5.Women of childbearing potential (defined as all women with the physiological conditions necessary for pregnancy) and men who are unwilling or unable to use effective contraception during pregnancy, during the study, and within 20 weeks after the last administration of the study drug; 6.Researchers consider any other circumstances that might hinder participants from following and completing the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 12 weeks PASI 90 response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 4, 8, 12, 24 weeks PASI 90 response rate;4, 8, 12, 24 weeks DLQI 0/1 response rate;4, 8, 12, 24 weeks PGA0/1 response rate;4, 8, 12, 24 weeks PASI 75, PASI 100 response rate; | — |
Countries
China
Contacts
Public ContactHong Liu
Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venerology, Shandong First Medical University & Shandong Academy of Medical Sciences
Outcome results
None listed